The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
| Autor: | Hongshun Ma, Wenhui Song |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty endocrine system diseases Adjuvant chemotherapy medicine.medical_treatment chemotherapy OncoTargets and Therapy 03 medical and health sciences Internal medicine medicine Urothelial cancer Pharmacology (medical) Clinical significance Brca1 gene Original Research Chemotherapy business.industry BRCA1 Oxaliplatin 030104 developmental biology urothelial cancer Immunohistochemistry prognosis ERCC1 business medicine.drug |
| Zdroj: | OncoTargets and therapy |
| ISSN: | 1178-6930 |
| Popis: | Wenhui Song, Hongshun MaDepartment of Urology, Tianjin First Center Hospital, Tianjin, People’s Republic of ChinaObjective: To investigate the expression and clinical significance of ERCC1 and BRCA1 genes in urothelial cancer patients.Methods: Forty-two urothelial cancer patients who did not receive platinum-based chemotherapy during January 2009 to May 2013 were enrolled. The expression levels of ERCC1 and BRCA1 were determined by immunohistochemistry and the median survival time (MST) for these patients was calculated.Results: ERCC1-positive patients who received oxaliplatin-based chemotherapy had a shorter MST than ERCC1-negative patients (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|